



PARAGARD IUD

BURNS 3.24.15

Learning Objectives


- ▶ Describe the mechanism and effectiveness of contraceptive procedures
- ▶ Counsel patients about the benefits, risks and use for each contraceptive method
- ▶ Describe barriers to effective contraceptive use and to the reduction of unintended pregnancy
- ▶ Describe common outpatient and inpatient gynecologic procedures with their indications and possible complications: contraceptive implants
- ▶ Prerequisites:
 - ▶ NONE
- ▶ See also – for closely related topics
 - ▶ FLAME LECTURES 149A-C – Combined Hormonal Contraceptives
 - ▶ FLAME LECTURE 150 – Barrier contraceptive methods
 - ▶ FLAME LECTURE 152 – Nexplanon
 - ▶ FLAME LECTURE 153 – Mirena IUD for contraception
 - ▶ FLAME LECTURE 154 – Paragard for contraception
 - ▶ FLAME LECTURE 149A2 – The Contraceptive Counseling Visit
 - ▶ FLAME LECTURE 154B – Emergency Contraception

Paragard

- ▶ Known as one of the four types of **long-acting reversible contraceptives** (LARCs)
- ▶ T-shaped intrauterine device (IUD) that is **hormone-free** because it is made a plastic T surrounded by a copper coil
- ▶ Mechanism(s) of action:
 - ▶ Copper is **spermicidal**, **inhibits sperm motility**, **inhibits acrosomal enzymes** so sperm can't fertilize egg, and **facilitates endometrial phagocytosis of sperm**
 - ▶ The Paragard does not interfere with fertilized egg, thus not an abortifacient
- ▶ Approved for 10 years, but effective up to 12 years

EFFECTIVENESS OF FAMILY PLANNING METHODS*


*The percentages indicate the number out of every 100 women who experienced an unintended pregnancy within the first year of typical use of each contraceptive method.




PARAGARD IUD

Perfect use: 0.6% failure in 1st year

Typical use: 0.8% failure in 1st year



Other Methods of Contraception: (1) Lactational Amenorrhea Method (LAM) is a highly effective, temporary method of contraception; and (2) Emergency Contraception: emergency contraceptive pills or a copper IUD after unprotected intercourse substantially reduce risk of pregnancy. Adapted from World Health Organization (WHO) Department of Reproductive Health and Research, Johns Hopkins Bloomberg School of Public Health, Center for Communications Programs (CCP), Knowledge for Health project. Family planning: a global handbook for providers (2017 update). Baltimore, MD: Geneva, Switzerland: CCP and WHO, 2017; and Trussard, J. Contraceptive failure in the United States. Contraception 2011;83:297-304.



ADVANTAGES

- ▶ Very high efficacy
- ▶ Convenient, requires no action at time of intercourse
- ▶ High continuation rate in clinical trials
- ▶ Effective option for women who don't want/cannot use hormonal methods
- ▶ Fewer prescribing precautions than Mirena IUD & other hormonal options
- ▶ Possible protection against endometrial cancer and cervical cancer
- ▶ Rapid return to fertility when desired
- ▶ Cost effective – without any assistance ~ \$475 over 10-12 years (=\$40-47/year)
- ▶ Safe contraceptive for women at increased risk for DVT or PE or with thrombogenic mutations
- ▶ Can be used as emergency contraceptive

DISADVANTAGES

- ▶ Increased menstrual bleeding (up to 50% increase)
- ▶ May cause cramping following insertion, , especially in nulliparous patients
- ▶ No protection against STI's
- ▶ Some women can experience spontaneous expulsion (likelihood decreases over time)
- ▶ If strings too short or cut improperly can cause partner discomfort during sex
- ▶ Limitations in access:
 - ▶ Requires access to physician properly trained in insertion & removal
- ▶ Prescribing precautions
 - ▶ Pregnancy
 - ▶ Uterus < 6cm or > 9cm
 - ▶ Severe anemia
 - ▶ Active STI or PID
 - ▶ Wilson's disease / Copper allergy
 - ▶ Uterine anatomical abnormality
 - ▶ Known/suspected uterine / cervical CA

Mirena/Skyla vs. Paragard

| Mirena (Hormonal IUD) | Paragard (Copper IUD) |
|--|---|
| Effective for at least 5 yrs | Effective for at least 12 yrs |
| Lighter to no periods | Heavier periods and/or more cramping |
| Irregular bleeding common in first few months; hormonal side effects | No intermenstrual spotting; no hormones/hormonal side effects |
| Treats menorrhagia / dysmenorrhea | Can be used as emergency contraceptive |

What about *Skyla*?


- Skyla is a hormonal IUD that releases levonorgestrel just like the Mirena
- However, the dose is lower (13.5 mcg/day vs. 20 mcg/day) which may lead to less hormonal side effects (but also last a shorter amount of time; only 3 years)
- Skyla frame and inserter are smaller, easier and more comfortable to insert
- FDA-approved in nulliparous women (also true of Paragard)

TIMING OF INSERTION

- ▶ QUICK START METHOD (“LMP” = FIRST day of bleeding):
 - ▶ If LMP < 5 days ago → PLACE IT
 - ▶ If LMP 5-10 days ago → Upreg neg → PLACE IT (If pregnancy not desired in that it may function as emergency contraception)
 - ▶ If LMP was > 10 days ago → Upreg neg → if abstinence OR perfect contraceptive use → PLACE IT
 - ▶ If LMP was > 10 days ago → Upreg neg → if imperfect contraceptive use → DO NOT PLACE → Give alt form + Upreg in 3 weeks
- ▶ Post-delivery/Post-abortion: May be inserted immediately following delivery/abortion, or 4-8 weeks following

INSERTION²

1. Most women don't need anesthetic, but NSAIDs or a paracervical block can be performed, especially in nulliparous women
2. Check position, size, and mobility of uterus with bimanual exam
3. Insert speculum and place tenaculum to stabilize cervix
4. Assess (sound) intrauterine length by gently placing a sound or the device itself up to the fundus to ensure uterus is between 6-9 cm
5. Load IUD into insertion tube by bending arms
6. Arrange to slider to the distance sounded (see image on right), and push flange up to load IUD into the tube thus tucking the arms
7. Gently insert tube into cervical canal, holding the flange with thumb to prevent prematurely releasing the IUD. Stop when reaching the fundus or when the slider reaches the cervical os
8. Pull the inserter tube back ~1 cm while holding the white rod steady so that IUD arms are released
9. Gently push the inserter tube back into uterus so that the IUD is placed against the fundus
10. Pull back the white rod from inserter tube
11. Withdraw inserter tube and cut the threads, leaving 2-3 cm visible outside cervix.



FOLLOW-UP & PROBLEM MANAGEMENT^{1,3}

- ▶ Patient should return 4-6 weeks after insertion to verify IUD is still in place and that no problems have occurred
- ▶ Patient should also be instructed on how to check for strings so they can self-check monthly (usually after every period)
- ▶ **Expulsion/Partial Expulsion:**
 - ▶ Rates: 3-5% following routine placement, 5-8% immediate post-abortion, 25% immediate post-delivery
 - ▶ May present with bleeding or pain but can often be expelled without patient noticing
 - ▶ If expulsion suspected: Confirm expulsion using pelvic ultrasound
 - ▶ If expulsion confirmed: Rule out pregnancy, then can replace with new IUD
- ▶ **Missing strings**
 - ▶ It is not a problem to have missing strings, unless the IUD needs to come out
 - ▶ If missing, use U/S or AXR to check for extra-uterine IUD and test for pregnancy. If both negative, then can reinsert new IUD
 - ▶ If IUD needs to be removed, you can use a cytobrush or special graspers to remove under U/S guidance

FOLLOW-UP & PROBLEM MANAGEMENT^{1,3}


- ▶ **Embedment:** IUD embedded in myometrium, reducing effectiveness and causing discomfort; occurs very rarely
 - ▶ If diagnosed on U/S, can remove IUD and replace with new one
- ▶ **Uterine perforation:**
 - ▶ **Signs:** pain, loss of resistance to advancing instrument
 - ▶ Perforation during uterine sounding: remove sound, give antibiotics and observe
 - ▶ Patient stable: send home with alternate contraception
 - ▶ If pain persists or vital signs change, needs immediate laparoscopic evaluation
 - ▶ Perforation during IUD placement: remove IUD if possible, if not then do ultrasound and send for immediate laparoscopic evaluation
 - ▶ Asymptomatic perforation found later: arrange for elective laparoscopic removal
 - ▶ Not a contraindication for future IUD use

FOLLOW-UP & PROBLEM MANAGEMENT^{1,3}

- ▶ Cramping and/or pain:
 - ▶ Cramping after insertion lasts up to 2 weeks
 - ▶ If cramping persists, rule out pregnancy, infection, and expulsion and consider alternative contraceptive
- ▶ Infection
 - ▶ *BV / Candidiasis*: treat routinely
 - ▶ *Trichomoniasis*: treat routinely and discuss condom use/STI protection
 - ▶ *Cervicitis / PID*: Give first dose of antibiotics before consider removing IUD. If patient shows improvement after first dose, may not need IUD removal. If patient does not improve, remove IUD. Either way continue standard treatment.
 - ▶ *Actinomyces*: ~7% of IUD users are colonizers of *Actinomyces* (often noted on pap)
 - ▶ If no signs of infection, continue to observe with annual pap smears
 - ▶ If sign of PID, treat with penicillin G (2 wks), doxycycline (2 wks), or tetracycline (1 month) AND remove IUD because the bacteria bind to this foreign body, repeat Pap smear, and reinsert a new IUD once infection is cleared

DISCONTINUATION²

- ▶ ***Fertility returns immediately after discontinuation***
- ▶ Paragard IUDs should be replaced after 10-12 years
- ▶ Remove by gently pulling on strings with forceps
 - ▶ If no strings are visible, can remove using alligator forceps
- ▶ Removal may some cause pain and/or bleeding
- ▶ Examine removed Paragard to ensure it is intact



Paragard as Emergency Contraception¹

| | Paragard IUD | Plan B / POP EC |
|--------------------------|---|--|
| TIMING AFTER INTERCOURSE | Up to 8 days after ovulation, usually within 5 days of unprotected intercourse | ASAP but can be used up to 5 days after unprotected intercourse (Sooner is more effective) |
| DOSE | Non-hormonal copper IUD | 2 doses of .75mg levonogestrel 12 hrs apart or single 1.5mg dose |
| PREGNANCY / 100 WOMEN | .1-.2 % | <12hr: .4% 1-3 days: 2.7% (Avg: 1.1%) |
| ADVANTAGES | Effective long-term contraception | Available over-the-counter |
| DISADVANTAGES | More expensive, requires physicians visit and insertion procedure, more prescribing precautions | Less effective, requires more immediate action |
| SIDE EFFECTS | Pain, bleeding, expulsion | Spotting, hormonal side effects (nausea, vomiting, moodiness) |

- 1 = No restriction for the use of the contraceptive method.
- 2 = Advantages of using the method generally outweigh the theoretical or proven risks.
- 3 = Theoretical or proven risks usually outweigh the advantages of using the method.
- 4 = Unacceptable health risk if the contraceptive method is used.

CDC Guideline - Paragard

| | Initiation Continuation |
|--|---|
| Age | Menarche to <20 years = 2 ≥20 years = 1 |
| Parity | |
| Nulliparous | 2 |
| Parous | 1 |
| Postpartum (breastfeeding or nonbreastfeeding) | |
| <10 min after delivery of placenta | 2 |
| 10 min after delivery of placenta to <4weeks | 2 |
| ≥4 weeks | 1 |
| Peurperal sepsis | 4 |
| Postabortion | |
| First trimester | 1 |
| Second trimester | 2 |
| Immediate post-septic abortion | 4 |
| Past ectopic pregnancy | 1 |
| Smoking | |
| Age <35 years | 1 |
| Age >35 years | <15 Cig/day = 1 ≥15 Cig/day = 1 |
| Obesity | |
| BMI >30 | 1 |
| Menarche to <18 years + BMI ≥30 | 1 |
| History of Bariatric surgery that limits absorption of nutrients | 1 |
| Cardiovascular disease | |
| Multiple risk factors for arterial CV disease | 1 |
| Hypertension | Adequately controlled = 1 Systolic 140-159 or Diastolic 90-99 = 1 Systolic ≥ 160 or Diastolic ≥ 100 = 1 |
| Vascular disease | 1 |
| History of high blood pressure during pregnancy | 1 |
| Deep Vein Thrombosis / Pulmonary Embolism | History of DVT/PE, not on anticoagulant therapy = 1 Acute DVT/PE = 2 |
| Major surgery | Established DVT/PE, on anticoagulant therapy for at least 3 mo = 2 Family history = 1 With prolonged immobilization = 1 Without prolonged immobilization = 1 |

| | Initiation Continuation |
|--|---|
| Known thrombogenic mutations | 1 |
| Superficial venous thrombosis | a. Varicose veins = 1 b. Superficial thrombophlebitis = 1 |
| Current and history of ischemic heart disease | 1 |
| Stroke (history of cerebrovascular accident) | 1 |
| Known hyperlipidemias | 1 |
| Valvular heart disease | a. Uncomplicated = 1 b. Complicated§ (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis) = 1 |
| Peripartum Cardio-Myopathy | a. Normal or mildly impaired cardiac function (Patients with no limitation or slight/mild limitation of activities) = 2 b. Moderately or severely impaired cardiac function (Patients with marked limitation of activity or patients who should be at complete rest) = 2 |
| Rheumatic Diseases | |
| SLE | a. Positive (or unknown) antiphospholipid antibodies = 1 b. Severe thrombocytopenia = 3 2 c. Immunosuppressive treatment = 2 1 d. None of the above = 1 1 |
| Rheumatoid arthritis | a. On immunosuppressive therapy = 2 1 b. Not on immunosuppressive therapy = 1 |
| Neurologic conditions | |
| Headaches | |
| a. Non-migrainous (mild or severe) | 1 |
| b. Migraine | i. Without aura / <35 years = 1 Without aura / ≥35 years = 1 With aura = 1 |
| Epilepsy | 1 |
| Depressive disorders | 1 |
| Reproductive tract infections and disorders | |
| Vaginal bleeding patterns | a. Irregular pattern without heavy bleeding = 1 b. Heavy or prolonged bleeding (includes regular and irregular patterns) = 2 |
| Unexplained vaginal bleeding (suspicious for serious condition, before evaluation) | 4 2 |
| Endometriosis | 2 |
| Benign ovarian tumors (including cysts) | 1 |
| Severe dysmenorrhea | 2 |
| Gestational trophoblastic disease | a. Decreasing or undetectable beta-hCG levels = 3 b. Persistently elevated beta-hCG levels or malignant disease = 4 |
| Cervical ectropion | 1 |
| Cervical intraepithelial neoplasia | 1 |
| Cervical cancer (awaiting treatment) | 4 2 |
| Breast disease | a. Undiagnosed mass = 1 b. Benign breast disease = 1 c. Family history of cancer = 1 d. Breast cancer (current) = 1 e. Breast cancer (past / no evidence of current for 5 yrs) = 1 |

| | Initiation Continuation | Continuation |
|------------------------------------|--|--------------|
| Endometrial hyperplasia | 1 | 1 |
| Endometrial cancer | 4 2 | 2 |
| Ovarian cancer | 1 | 1 |
| Uterine fibroids | 2 | 2 |
| Anatomical abnormalities | Distorted uterine cavity = 4 Other abnormalities not distorting uterine cavity = 2 | |
| Pelvic inflammatory disease (PID) | a. Past PID without subsequent pregnancy = 1 1 b. Past PID with subsequent pregnancy = 2 2 c. Current PID = 4 2 | |
| STIs | Current purulent cervicitis or chlamydia, or gonorrhea = 4 2 Other STI's or Vaginitis = 2 2 | |
| HIV/AIDS | High risk for HIV = 2 2 HIV infection = 2 2 AIDS = 3 2 | |
| Other infections | Schistosomiasis = 1 Tuberculosis (pelvic) = 4 3 Malaria = 1 | |
| Endocrine Conditions | | |
| Diabetes | a. History of gestational disease = 1 b. Nonvascular disease (Type I or Type II) = 1 c. Nephropathy/retinopathy/ neuropathy = 1 d. Other vascular disease or diabetes of >20 yrs' = 1 | |
| Thyroid disorders | a. Simple goiter = 1 b. Hyperthyroid = 1 c. Hypothyroid = 1 | |
| Gastrointestinal conditions | | |
| Gallbladder disease | Inflammatory bowel disease (IBD) = 1 a. Symptomatic = 1 b. Asymptomatic = 1 | |
| History of cholestasis | a. Pregnancy-related = 1 b. Past COC-related = 1 | |
| Viral hepatitis | a. Acute or flare = 1 b. Carrier = 1 c. Chronic = 1 | |
| Cirrhosis | a. Mild (compensated) = 1 b. Severe (decompensated) = 1 | |
| Liver tumors | | |
| a. Benign | i. Focal nodular hyperplasia = 1 ii. Hepatocellular adenoma = 1 b. Malignant (hepatoma) = 1 | |
| Anemias | 2 | |
| Solid organ transplantation | Complicated = 3 2 Uncomplicated = 2 | |
| Drug Interactions | | |
| Antiretroviral Therapy | NRTI's = 2/3 2 nNRTI's = 2/3 2 Ritonavir-boosted protease inhibitors = 2/3 2 | |
| Anticonvulsant Therapy | Certain anticonvulsants = 1 Lamotrigine = 1 | |
| Antimicrobial Therapy | Broadpectrum Antibiotics, Antifungals, Antiparasitics = 1 Rifampicin therapy = 1 | |

IMPORTANT LINKS / REFERENCES

- ▶ [CDC US Medical Eligibility Criteria for Contraceptive Use Chart](#)
- 1. Managing Contraception 2012-2014
- 2. UpToDate “Insertion and removal of an intrauterine contraceptive device” February, 2015
- 3. UpToDate “Intrauterine contraception (IUD): Overview” February, 2015
- 4. UpToDate “Management of problems related to intrauterine contraception” February, 2015
- 5. Paipert et al. Continuation and satisfaction of reversible contraception. *Obstet Gynecol.* 2011;117(5):1105-13. doi: 10.1097/AOG.0b013e31821188ad

OTHER REFERENCES

